

Correction

Correction: Jose et al. Transferrin-Conjugated Docetaxel-PLGA Nanoparticles for Tumor Targeting: Influence on MCF-7 Cell Cycle. *Polymers* 2019, 11, 1905

Sajan Jose ^{1,2,*}, Thomas A. Cinu ¹, Rosmy Sebastian ¹, M. H. Shoja ³, N. A. Aleykutty ⁴, Alessandra Durazzo ⁵ , Massimo Lucarini ⁵, Antonello Santini ^{6,*}  and Eliana B. Souto ^{2,7,*} 

¹ Department of Pharmaceutical Sciences, Mahatma Gandhi University, Cheruvandoor Campus, Ettumanoor 686631, India

² CEB-Centre of Biological Engineering, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

³ College of Pharmaceutical Sciences, Manipal University, Manipal 576104, India

⁴ Caritas College of Pharmacy, Kottayam 686630, India

⁵ CREA—Research Centre for Food and Nutrition, Via Ardeatina 546, 00178 Rome, Italy

⁶ Department of Pharmacy, University of Napoli Federico II, Via D. Montesano 49, 80131 Napoli, Italy

⁷ Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra (FFUC), Pólo das Ciências da Saúde, 3000-548 Coimbra, Portugal

* Correspondence: sajanjose@hotmail.com (S.J.); asantini@unina.it (A.S.); ebsouto@ebsouto.pt (E.B.S.); Tel.: +91-9447600750 (S.J.); +39-081-253-9317 (A.S.); +351-239-488-400 (E.B.S.)

In the original publication [1], there was a mistake in Figure 7. Figure 7B,C (Untreated MCF7 Cells) and Figure 7D,E (Blank nano particle @2h) have, in fact, very low uptake and have almost the same data. However, when changing to drug-loaded nanoparticles and transferrin-conjugated drug-loaded nanoparticles, the uptake increases. When building the combined image, the panels D and E were misplaced. The correct Figure 7 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.



Citation: Jose, S.; Cinu, T.A.; Sebastian, R.; Shoja, M.H.; Aleykutty, N.A.; Durazzo, A.; Lucarini, M.; Santini, A.; Souto, E.B. Correction: Jose et al. Transferrin-Conjugated Docetaxel-PLGA Nanoparticles for Tumor Targeting: Influence on MCF-7 Cell Cycle. *Polymers* 2019, 11, 1905. *Polymers* 2023, 15, 189. <https://doi.org/10.3390/polym15010189>

Received: 10 May 2022

Accepted: 5 December 2022

Published: 30 December 2022



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).




Figure 7. Cellular uptake study using flow cytometry: (A) gating, (B,C) fluorescence of untreated MCF-7 cells, (D,E) fluorescence of blank nanoparticles at 2 h, (F,G) fluorescence of blank nanoparticles at 24 h, (H,I) fluorescence of unconjugated nanoparticles at 2 h, (J,K) fluorescence of unconjugated nanoparticles at 24 h, (L,M) fluorescence of DCT-loaded Tf-conjugated PLGA NPs at 2 h, (N,O) fluorescence of Tf-conjugated PLGA NP at 24 h. The *x*- and *y*-axes correspond to forward scatter (FSC) (which measures size) and side scatter (SSC) (which measures internal complexity), respectively. The FL1-area stands for total cell fluorescence.

Reference

1. Jose, S.; Cinu, T.A.; Sebastian, R.; Shoja, M.H.; Aleykutty, N.A.; Durazzo, A.; Lucarini, M.; Santini, A.; Souto, E.B. Transferrin-Conjugated Docetaxel-PLGA Nanoparticles for Tumor Targeting: Influence on MCF-7 Cell Cycle. *Polymers* **2019**, *11*, 1905. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.